PROK
ProKidney Corp.
Price Chart
Latest Quote
$1.83
+0.08 (+4.57%)
Current Price
| Previous Close | $1.75 |
| Open | $1.76 |
| Day High | $1.83 |
| Day Low | $1.75 |
| Volume | 578,592 |
Stock Information
| Shares Outstanding | 205.20M |
| Total Debt | $3.78M |
| Cash Equivalents | $224.94M |
| Revenue | $889K |
| Net Income | $-72.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $552.77M |
| EPS (TTM) | $-0.53 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.44B |
| Sales | $889K |
| Income | $-72.29M |
| Book/sh | $-7.21 |
| Cash/sh | $1.10 |
| Employees | 231 |
Financial Ratios
| Quick Ratio | 8.71 |
| Current Ratio | 9.06 |
| Debt/Eq | 1.44 |
Returns & Margins
| ROA | -30.15% |
| ROE | -49.37% |
| Gross Margin | 100.00% |
| Operating Margin | -19881.86% |
Ownership
| Insider Ownership | 47.72% |
| Institutional Ownership | 24.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.18 |
| P/S | 621.79 |
| P/B | -0.25 |
Analyst Data
| Recommendation | none |
| Target Price | $6.25 |
Technical Indicators
| SMA20 | $1.75 |
| SMA50 | $1.83 |
| SMA200 | $2.24 |
| RSI | 50.00 |
| ATR | 0.1199 |
| Shares Float | 156.76M |
| Short Float | 11.89% |
| Short Ratio | 21.17 |
| Volatility | 1.70 |
| Rel Volume | 0.63 |
Performance History
| Week | +10.24% |
| Month | +18.06% |
| Quarter | -6.15% |
| 6 Months | -16.82% |
| YTD | -17.94% |
| Year | +113.29% |
| 3 Years | -84.31% |
| 10 Years | -81.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.83 | 578,600 |
| 2026-06-17 | $1.75 | 755,700 |
| 2026-06-16 | $1.69 | 484,400 |
| 2026-06-15 | $1.67 | 570,000 |
| 2026-06-12 | $1.64 | 774,800 |
| 2026-06-11 | $1.66 | 587,800 |
| 2026-06-10 | $1.67 | 671,500 |
| 2026-06-09 | $1.67 | 465,800 |
| 2026-06-08 | $1.71 | 998,500 |
| 2026-06-05 | $1.80 | 1,520,200 |
| 2026-06-04 | $1.85 | 740,100 |
| 2026-06-03 | $1.73 | 838,100 |
| 2026-06-02 | $1.90 | 2,258,400 |
| 2026-06-01 | $1.85 | 1,467,100 |
| 2026-05-29 | $1.83 | 1,002,400 |
| 2026-05-28 | $1.81 | 1,098,300 |
| 2026-05-27 | $1.81 | 1,372,200 |
| 2026-05-26 | $1.69 | 895,200 |
| 2026-05-22 | $1.75 | 479,700 |
| 2026-05-21 | $1.75 | 876,700 |
| 2026-05-20 | $1.69 | 1,278,700 |
| 2026-05-19 | $1.55 | 891,600 |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
đ° Latest News
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencelâs Accelerated Approval Path
Insider Monkey âĸ 2026-06-17T15:16:52Z
Identiv And Two Other Penny Stocks To Watch Closely
Simply Wall St. âĸ 2026-06-05T18:15:20Z
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-15T16:55:01Z
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-15T11:10:02Z
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-14T12:45:04Z
3 Promising Penny Stocks With Market Caps Up To $600M
Simply Wall St. âĸ 2026-05-06T18:05:45Z
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel
Insider Monkey âĸ 2026-05-01T09:23:41Z
April 2026 Penny Stock Highlights
Simply Wall St. âĸ 2026-04-03T18:05:10Z
What Makes ProKidney Corp. (PROK) So Attractive
Insider Monkey âĸ 2026-03-31T07:19:11Z
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-12T23:20:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $893,000 | $76,000 | $0 | $0 |
| Operating Revenue | $893,000 | $76,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $4,000 | $9,000 | $12,000 | $215,000 |
| Total Expenses | $165,900,000 | $183,752,000 | $151,522,000 | $153,007,000 |
| Net Non Operating Interest Income Expense | $13,809,000 | $19,743,000 | $22,071,000 | $5,768,000 |
| Interest Expense Non Operating | $4,000 | $9,000 | $12,000 | $215,000 |
| Operating Expense | $165,900,000 | $183,752,000 | $151,522,000 | $153,007,000 |
| General And Administrative Expense | $51,777,000 | $56,084,000 | $44,815,000 | $70,937,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-68,986,000 | $-61,186,000 | $-35,468,000 | $-108,032,000 |
| Net Interest Income | $13,809,000 | $19,743,000 | $22,071,000 | $5,768,000 |
| Interest Income | $13,813,000 | $19,752,000 | $22,083,000 | $5,983,000 |
| Normalized Income | $-68,986,000 | $-61,186,000 | $-35,468,000 | $-108,032,000 |
| Net Income From Continuing And Discontinued Operation | $-68,986,000 | $-61,186,000 | $-35,468,000 | $-108,032,000 |
| Total Operating Income As Reported | $-165,007,000 | $-183,676,000 | $-151,522,000 | $-153,007,000 |
| Net Income Common Stockholders | $-68,986,000 | $-61,186,000 | $-35,468,000 | $-108,032,000 |
| Net Income | $-68,986,000 | $-61,186,000 | $-35,468,000 | $-108,032,000 |
| Net Income Including Noncontrolling Interests | $-151,612,000 | $-163,335,000 | $-135,447,000 | $-148,135,000 |
| Net Income Continuous Operations | $-151,612,000 | $-163,335,000 | $-135,447,000 | $-148,135,000 |
| Pretax Income | $-151,198,000 | $-163,933,000 | $-129,451,000 | $-147,239,000 |
| Interest Income Non Operating | $13,813,000 | $19,752,000 | $22,083,000 | $5,983,000 |
| Operating Income | $-165,007,000 | $-183,676,000 | $-151,522,000 | $-153,007,000 |
| Per Share | ||||
| Diluted EPS | $-0.52 | $-0.62 | $-0.57 | $-0.23 |
| Basic EPS | $-0.52 | $-0.62 | $-0.57 | $-0.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-144,619,000 | $-158,492,000 | $-125,586,000 | $-143,988,000 |
| Reconciled Depreciation | $6,575,000 | $5,432,000 | $3,853,000 | $3,036,000 |
| EBITDA (Bullshit earnings) | $-144,619,000 | $-158,492,000 | $-125,586,000 | $-143,988,000 |
| EBIT | $-151,194,000 | $-163,924,000 | $-129,439,000 | $-147,024,000 |
| Diluted Average Shares | $133,942,736 | $97,916,193 | $61,714,225 | $61,540,231 |
| Basic Average Shares | $133,942,736 | $97,916,193 | $61,714,225 | $61,540,231 |
| Diluted NI Availto Com Stockholders | $-68,986,000 | $-61,186,000 | $-35,468,000 | $-108,032,000 |
| Minority Interests | $82,626,000 | $102,149,000 | $99,979,000 | $40,103,000 |
| Tax Provision | $414,000 | $-598,000 | $5,996,000 | $896,000 |
| Research And Development | $114,123,000 | $127,668,000 | $106,707,000 | $82,070,000 |
| Selling General And Administration | $51,777,000 | $56,084,000 | $44,815,000 | $70,937,000 |
| Other Gand A | $51,777,000 | $56,084,000 | $44,815,000 | $70,937,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,011,197,000 | $-994,954,000 | $-1,103,396,000 | $-1,096,829,000 |
| Total Assets | $335,574,000 | $441,073,000 | $420,552,000 | $517,996,000 |
| Total Non Current Assets | $54,895,000 | $45,189,000 | $46,406,000 | $13,277,000 |
| Current Assets | $280,679,000 | $395,884,000 | $374,146,000 | $504,719,000 |
| Other Current Assets | $2,804,000 | $80,000 | $9,000 | $1,384,000 |
| Assets Held For Sale Current | $0 | $19,368,000 | $0 | - |
| Prepaid Assets | $6,731,000 | $15,697,000 | $9,812,000 | $13,083,000 |
| Receivables | $1,127,000 | $2,447,000 | $1,375,000 | $0 |
| Accrued Interest Receivable | $1,127,000 | $2,447,000 | $1,375,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $270,017,000 | $358,292,000 | $362,950,000 | $490,252,000 |
| Cash And Cash Equivalents | $108,537,000 | $99,120,000 | $60,649,000 | $490,252,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $213,000 |
| Debt | ||||
| Total Debt | $4,036,000 | $3,236,000 | $4,413,000 | $2,399,000 |
| Long Term Debt And Capital Lease Obligation | $2,965,000 | $2,471,000 | $3,610,000 | $1,906,000 |
| Current Debt And Capital Lease Obligation | $1,071,000 | $765,000 | $803,000 | $493,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,781,000 | $39,436,000 | $29,216,000 | $13,057,000 |
| Total Non Current Liabilities Net Minority Interest | $4,039,000 | $3,219,000 | $4,178,000 | $2,184,000 |
| Tradeand Other Payables Non Current | $1,074,000 | $748,000 | $568,000 | $278,000 |
| Current Liabilities | $30,742,000 | $36,217,000 | $25,038,000 | $10,873,000 |
| Payables And Accrued Expenses | $17,834,000 | $23,999,000 | $16,715,000 | $7,025,000 |
| Payables | $940,000 | $4,315,000 | $6,570,000 | $3,044,000 |
| Total Tax Payable | $0 | $682,000 | $1,472,000 | $0 |
| Income Tax Payable | $0 | $682,000 | $1,472,000 | $0 |
| Accounts Payable | $940,000 | $3,633,000 | $5,098,000 | $3,044,000 |
| Equity | ||||
| Common Stock Equity | $-1,011,197,000 | $-994,954,000 | $-1,103,396,000 | $-1,096,616,000 |
| Total Equity Gross Minority Interest | $300,793,000 | $401,637,000 | $391,336,000 | $504,939,000 |
| Stockholders Equity | $-1,011,197,000 | $-994,954,000 | $-1,103,396,000 | $-1,096,616,000 |
| Gains Losses Not Affecting Retained Earnings | $56,000 | $130,000 | $130,000 | $0 |
| Other Equity Adjustments | $56,000 | $130,000 | $130,000 | - |
| Retained Earnings | $-1,269,835,000 | $-1,200,849,000 | $-1,139,663,000 | $-1,104,116,000 |
| Other | ||||
| Ordinary Shares Number | $141,807,277 | $128,054,417 | $59,880,347 | $61,540,231 |
| Share Issued | $141,807,277 | $128,054,417 | $59,880,347 | $61,540,231 |
| Tangible Book Value | $-1,011,197,000 | $-994,954,000 | $-1,103,396,000 | $-1,096,829,000 |
| Invested Capital | $-1,011,197,000 | $-994,954,000 | $-1,103,396,000 | $-1,096,616,000 |
| Working Capital | $249,937,000 | $359,667,000 | $349,108,000 | $493,846,000 |
| Capital Lease Obligations | $4,036,000 | $3,236,000 | $4,413,000 | $2,399,000 |
| Total Capitalization | $-1,011,197,000 | $-994,954,000 | $-1,103,396,000 | $-1,096,616,000 |
| Minority Interest | $1,311,990,000 | $1,396,591,000 | $1,494,732,000 | $1,601,555,000 |
| Additional Paid In Capital | $258,552,000 | $205,736,000 | $36,114,000 | $7,476,000 |
| Capital Stock | $30,000 | $29,000 | $23,000 | $24,000 |
| Common Stock | $30,000 | $29,000 | $23,000 | $24,000 |
| Long Term Capital Lease Obligation | $2,965,000 | $2,471,000 | $3,610,000 | $1,906,000 |
| Current Capital Lease Obligation | $1,071,000 | $765,000 | $803,000 | $493,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,837,000 | $11,453,000 | $7,520,000 | $3,355,000 |
| Current Accrued Expenses | $16,894,000 | $19,684,000 | $10,145,000 | $3,981,000 |
| Net PPE | $54,895,000 | $45,189,000 | $46,406,000 | $13,064,000 |
| Accumulated Depreciation | $-16,552,000 | $-11,032,000 | $-7,642,000 | $-4,708,000 |
| Gross PPE | $71,447,000 | $56,221,000 | $54,048,000 | $17,772,000 |
| Leases | $22,263,000 | $21,822,000 | $10,950,000 | $10,537,000 |
| Construction In Progress | $14,705,000 | $2,447,000 | $8,741,000 | $1,614,000 |
| Other Properties | $3,664,000 | $2,967,000 | $4,263,000 | $2,356,000 |
| Machinery Furniture Equipment | $8,315,000 | $6,485,000 | $4,537,000 | $3,265,000 |
| Buildings And Improvements | $21,095,000 | $21,095,000 | $22,490,000 | $0 |
| Land And Improvements | $1,405,000 | $1,405,000 | $3,067,000 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $161,480,000 | $259,172,000 | $302,301,000 | $0 |
| Total Partnership Capital | - | - | - | - |
| Limited Partnership Capital | - | - | - | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-135,313,000 | $-155,860,000 | $-124,266,000 | $-78,935,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-120,117,000 | $-126,351,000 | $-90,069,000 | $-77,089,000 |
| Cash Flow From Continuing Operating Activities | $-120,117,000 | $-126,351,000 | $-90,069,000 | $-77,089,000 |
| Operating Gains Losses | $-1,986,000 | $-6,939,000 | $-5,995,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-15,196,000 | $-29,509,000 | $-34,197,000 | $-1,846,000 |
| Investing Cash Flow | $103,965,000 | $20,414,000 | $-329,983,000 | $-1,738,000 |
| Cash Flow From Continuing Investing Activities | $103,965,000 | $20,414,000 | $-329,983,000 | $-1,738,000 |
| Net Other Investing Changes | $18,215,000 | - | - | $108,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-9,499,000 | $0 |
| Issuance Of Capital Stock | $24,247,000 | $144,322,000 | $0 | $0 |
| Financing Cash Flow | $25,569,000 | $144,408,000 | $-9,551,000 | $548,521,000 |
| Cash Flow From Continuing Financing Activities | $25,569,000 | $144,408,000 | $-9,551,000 | $548,521,000 |
| Net Common Stock Issuance | $24,247,000 | $144,322,000 | $-9,499,000 | $0 |
| Common Stock Issuance | $24,247,000 | $144,322,000 | $0 | $0 |
| Net Other Financing Charges | - | - | - | $548,553,000 |
| Other | ||||
| Repayment Of Debt | $-26,000 | $-54,000 | $-52,000 | $-35,032,000 |
| End Cash Position | $108,537,000 | $99,120,000 | $60,649,000 | $490,252,000 |
| Beginning Cash Position | $99,120,000 | $60,649,000 | $490,252,000 | $20,558,000 |
| Changes In Cash | $9,417,000 | $38,471,000 | $-429,603,000 | $469,694,000 |
| Proceeds From Stock Option Exercised | $1,348,000 | $140,000 | $0 | $0 |
| Common Stock Payments | $0 | $0 | $-9,499,000 | $0 |
| Net Issuance Payments Of Debt | $-26,000 | $-54,000 | $-52,000 | $-32,000 |
| Net Long Term Debt Issuance | $-26,000 | $-54,000 | $-52,000 | $-32,000 |
| Long Term Debt Payments | $-26,000 | $-54,000 | $-52,000 | $-32,000 |
| Net Investment Purchase And Sale | $100,946,000 | $49,923,000 | $-295,786,000 | $0 |
| Sale Of Investment | $318,022,000 | $373,946,000 | $175,818,000 | $0 |
| Purchase Of Investment | $-217,076,000 | $-324,023,000 | $-471,604,000 | $0 |
| Net PPE Purchase And Sale | $-15,196,000 | $-29,509,000 | $-34,197,000 | $-1,846,000 |
| Purchase Of PPE | $-15,196,000 | $-29,509,000 | $-34,197,000 | $-1,846,000 |
| Change In Working Capital | $1,281,000 | $3,956,000 | $16,674,000 | $-6,459,000 |
| Change In Payables And Accrued Expense | $-6,275,000 | $10,983,000 | $13,401,000 | $772,000 |
| Change In Payable | $-6,275,000 | $10,983,000 | $13,401,000 | $772,000 |
| Change In Account Payable | $-5,919,000 | $11,592,000 | $11,639,000 | $494,000 |
| Change In Tax Payable | $-356,000 | $-609,000 | $1,762,000 | $278,000 |
| Change In Income Tax Payable | $-356,000 | $-609,000 | $1,762,000 | $278,000 |
| Change In Prepaid Assets | $6,236,000 | $-5,955,000 | $4,648,000 | $-7,231,000 |
| Change In Receivables | $1,320,000 | $-1,072,000 | $-1,375,000 | $0 |
| Other Non Cash Items | $-29,000 | $-161,000 | - | - |
| Stock Based Compensation | $25,336,000 | $29,372,000 | $30,846,000 | $74,469,000 |
| Asset Impairment Charge | $318,000 | $5,324,000 | $0 | $0 |
| Depreciation Amortization Depletion | $6,575,000 | $5,432,000 | $3,853,000 | $3,036,000 |
| Depreciation And Amortization | $6,575,000 | $5,432,000 | $3,853,000 | $3,036,000 |
| Gain Loss On Investment Securities | $-3,417,000 | $-6,995,000 | $-6,018,000 | - |
| Gain Loss On Sale Of PPE | $1,431,000 | $56,000 | $23,000 | $0 |
| Net Income From Continuing Operations | $-151,612,000 | $-163,335,000 | $-135,447,000 | $-148,135,000 |
| Issuance Of Debt | - | $0 | $0 | $35,000,000 |
| Income Tax Paid Supplemental Data | - | $73,000 | $2,857,000 | $1,950,000 |
| Net Short Term Debt Issuance | - | $0 | $0 | $0 |
| Short Term Debt Payments | - | $0 | $0 | $-35,000,000 |
| Short Term Debt Issuance | - | $0 | $0 | $35,000,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-06-21